ClinicalTrials.gg
Not yet recruitingNCT02129751Updated Sep 29, 2026

Efficacy and Safety of Bupropion Hydrobromide in Adolescents and Children With Major Depressive Disorder

A Phase 4 interventional study of bupropion hydrobromide and Placebo in Major Depressive Disorder, sponsored by Bausch Health Americas, Inc.. Not yet recruiting. Open to participants aged 7 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Bausch Health Americas, Inc. (part of Bausch Health Companies Inc.) · Phase 4, Interventional, and Treatment

Updated Sep 29, 2026Start date movedPrimary completion moved+2 moreGo to Updates ↓
Phase
Phase 4
Study type
Interventional
Enrollment
246
Allocation
Randomized
Ages
7 Years to 17 Years
Sex
All
01

Study summary

Double-Blind, Placebo-Controlled, Multicenter Study of Efficacy and Safety

Read the detailed description
  • The primary efficacy endpoint is the mean change from Baseline to EOT in total CDRS-R (raw) score.
  • The secondary efficacy endpoints include:

    • Proportion of subjects characterized as responders at EOT (≥40% improvement from Baseline total CDRS-R raw score)
    • Proportion of subjects characterized as in remission at EOT (total CDRS-R raw score \<29)
    • Mean change from Baseline to EOT in CGI-C.

Safety endpoints include:

  • Incidence of AEs
  • Change from Baseline to EOT in vital signs (blood pressure and radial pulse rate), blood and urine laboratory panel, and ECG
  • Treatment discontinuation due to AEs
  • Suicidality as assessed by the C-SSRS score
  • Change from Baseline to EOT in sleep as assessed by the sleep subscale of the CDRS-R.
02

Conditions studied

  • Major Depressive Disorder

Keywords

  • able to swallow medications without difficulty
  • bupropion hydrobromide
03

In context

Depressive Disorder, Major

3,041 studies on the registry are indexed under Depressive Disorder, Major; 588 are open to participants now.

This study's planned enrollment of 246 is above the median of 79 across 2,530 interventional studies indexed under Depressive Disorder, Major.

Browse Depressive Disorder, Major studies →

Lead sponsor

Bausch Health Americas, Inc. is the lead sponsor of 213 studies on the registry; 7 are open to participants now.

Of its 25 completed or terminated interventional studies of FDA-regulated products, 18 (72%) have results posted.

First submitted after Bausch Health Americas, Inc. became part of Bausch Health Companies Inc..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
7 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female outpatients aged ≥7 to \<18 years (at Screening Visit 1).
  • Provide assent (subject) and written (parent/legal representative) and Health Insurance Portability and Accountability Act (HIPAA) for study participation (at Screening Visit 1).
  • Meet diagnostic criteria for MDD as defined in the DSM IV-TR5 at Screening Visits 1 and 1a (K-SADS-PL; see Appendix 17.2).
  • Current depressive episode of at least 4 weeks' duration as noted in the subject's history (Screening Visit 1).
  • Total CDRS-R raw score ≥45 at both the Screening and Baseline Visits (Visits 1 and 2) (see Appendix 17.3).
  • CGI-S score of ≥4 at the Baseline Visit (Visit 2) (see Appendix 17.4).

Exclusion criteria

Exclusion Criteria:

  • are unable to swallow medications without difficulty
  • have known to bupropion hydrobromide
  • are pregnant or planning to get pregnant or are lactating
  • Women of childbearing age unable to use at least one method of effective for the duration of the study
  • Previous history of attempted suicide
  • are unable to understand and communicate effectively with parent, Investigator, and study coordinator
  • are at immediate risk of requiring hospitalization, in the Investigator's opinion
  • have current seizure disorder or history of seizures or head trauma
  • have history or presence of medical conditions or clinically important laboratory abnormalities
  • have or physical examination abnormality at screening
  • have body weight less than the 3rd percentile or greater than the 97th percentile for age.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
246 participants (estimated)

Study arms

  • Experimental
    bupropion hydrobromide

    study drug

    Drug: bupropion hydrobromide

  • Placebo comparator
    placebo

    placebo

    Drug: Placebo

Interventions

  • Drugbupropion hydrobromide

    study drug

    Also known as: Aplenzin

  • DrugPlacebo

    placebo arm

06

What researchers measure

Primary outcomes

  1. Mean change from Baseline to EOT in total CDRS-R (raw) score

    Change from Baseline to EOT in total Children's Depression Rating Scale - Revised (CDRS-R). A higher score indicates a more profound state of depression. The interviewer rates 17 symptom areas; the symptom scores are summed to generate a total score. The total score ranges from 17 to 108.

    Time frame: Baseline and 2 years

07

Study locations

No study locations are listed for this record.

08

Updates

1 registry update since Sep 25, 2026
Start date
Jun 2026→Jul 1, 2027
Sep 29, 2026
Primary completion
Jul 2029→Jul 2030
Sep 29, 2026
Study completion
Dec 2029→Dec 2030
Sep 29, 2026
Contact
Study contact changed: j•••@bauschhealth.com · •••8205→w•••@bauschhealth.com · •••8552. See the current contact
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    Start date Jun 2026→Jul 1, 2027
    Primary completion Jul 2029→Jul 2030
    Study completion Dec 2029→Dec 2030
    Contact Study contact changed: j•••@bauschhealth.com · •••8205→w•••@bauschhealth.com · •••8552. See the current contact
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT02129751
Responsible party
Sponsor
First posted
May 2, 2014
Start date
Jul 1, 2027 (estimated)
Primary completion
Jul 2030 (estimated)
Completion
Dec 2030 (estimated)
Last update
Sep 29, 2026

Study contacts

Wendy Walton
Contact
wendy.walton@bauschhealth.com
505-917-8552
Angela Moore
study director · Bausch Health US, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion